Trulicity side effects: what the label reports
The short answer
The most common Trulicity side effects in the label's placebo-controlled trials were nausea (12.4% on 0.75 mg and 21.1% on 1.5 mg, against 5.3% on placebo), diarrhea (8.9% and 12.6%), vomiting (6.0% and 12.7%), abdominal pain (6.5% and 9.4%) and decreased appetite (4.9% and 8.6%). The trials enrolled adults with type 2 diabetes. Tell your prescriber about severe abdominal pain or dehydration.
Key takeaways
- Nausea, diarrhea, vomiting, abdominal pain and decreased appetite lead the table for adults with type 2 diabetes on Trulicity.
- Low blood sugar depends on your other medicines. Insulin or a sulfonylurea may raise the risk, including severe low blood sugar.
- Trulicity carries a boxed warning, the strongest kind the FDA requires, about thyroid C-cell tumors.
- It must not be used with a personal or family history of medullary thyroid carcinoma or with MEN 2.
- Call your prescriber about severe abdominal pain or dehydration. A serious allergic reaction needs urgent medical care.
On this page
- What are the most common side effects of Trulicity?
- Are side effects worse at 3 mg and 4.5 mg?
- How common are stomach side effects on Trulicity?
- Does Trulicity cause low blood sugar?
- What is the boxed warning, and what are the serious side effects?
- How many people stop Trulicity because of side effects?
- When to call your prescriber
- Frequently asked questions
- Sources
How often it was reported in the label's trials
| Reaction | Placebon=568 | 0.75 mgn=836 | 1.5 mgn=834 |
|---|---|---|---|
| Nausea | 5.3% | 12.4% | 21.1% |
| Diarrhea | 6.7% | 8.9% | 12.6% |
| Vomiting | 2.3% | 6% | 12.7% |
| Abdominal Pain | 4.9% | 6.5% | 9.4% |
| Decreased Appetite | 1.6% | 4.9% | 8.6% |
| Dyspepsia | 2.3% | 4.1% | 5.8% |
| Fatigue | 2.6% | 4.2% | 5.6% |
| Reaction | 1.5 mgn=612 | 3 mgn=616 | 4.5 mgn=614 |
|---|---|---|---|
| Nausea | 13.4% | 15.6% | 16.4% |
| Diarrhea | 7% | 11.4% | 10.7% |
| Vomiting | 5.6% | 8.3% | 9.3% |
| Dyspepsia | 2.8% | 5% | 2.6% |
| Reaction | Placebon=177 | 0.75 mgn=302 | 1.5 mgn=304 |
|---|---|---|---|
| Hypoglycemia with a glucose level <54 mg/dL | 0% | 0.3% | 0.7% |
| Severe hypoglycemia | 0% | 0% | 0% |
| Reaction | Placebon=141 | 0.75 mgn=280 | 1.5 mgn=279 |
|---|---|---|---|
| Hypoglycemia with a glucose level <54 mg/dL | 1.4% | 2.1% | 0% |
| Severe hypoglycemia | 0% | 0% | 0% |
| Reaction | Placebon=60 | 0.75 mg | 1.5 mgn=239 |
|---|---|---|---|
| Hypoglycemia with a glucose level <54 mg/dL | 0% | Not listed | 3.3% |
| Severe hypoglycemia | 0% | Not listed | 0% |
| Reaction | Placebon=150 | 0.75 mg | 1.5 mgn=150 |
|---|---|---|---|
| Hypoglycemia with a glucose level <54 mg/dL | 9.3% | Not listed | 14.7% |
| Severe hypoglycemia | 0% | Not listed | 0.7% |
| Reaction | Placebon=140 | 0.75 mgn=141 | 1.5 mgn=142 |
|---|---|---|---|
| Hypoglycemia with a glucose level <54 mg/dL | 0.7% | 0.7% | 0.7% |
| Severe hypoglycemia | 0% | 0.7% | 0% |
Trulicity: Gastrointestinal adverse reactions
In the pool of placebo-controlled trials, gastrointestinal (GI) adverse reactions occurred more frequently among patients who received TRULICITY compared to patients who received placebo (placebo 21%, 0.75 mg 32%, 1.5 mg 41%).
Trulicity: Constipation, flatulence, abdominal distension, reflux and eructation
The following GI adverse reactions were reported more frequently in TRULICITY-treated patients than placebo -treated patients (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).
Trulicity: Hypoglycemia with a sulfonylurea
Hypoglycemia was more frequent when TRULICITY was used in combination with a sulfonylurea or insulin than when used with non-secretagogues. In a 78-week adult clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 20% and 21% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea.
Trulicity: Hypoglycemia with prandial insulin
In a 52-week adult clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 77% and 69% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin.
Trulicity: Cholelithiasis and cholecystitis
In a cardiovascular outcomes trial in adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors with a median follow up of 5.4 years [see Clinical Studies 14.5], cholelithiasis occurred at a rate of 0.62/100 patient-years in TRULICITY-treated patients and 0.56/100 patient-years in placebo-treated patients after adjusting for prior cholecystectomy. Serious events of acute cholecystitis were reported in 0.5% and 0.3% of patients on TRULICITY and placebo respectively.
Trulicity: Heart rate increase
In adult patients, TRULICITY 0.75 mg and 1.5 mg resulted in a mean increase in heart rate (HR) of 2-4 beats per minute (bpm).
Trulicity: Sinus tachycardia
Sinus tachycardia was reported in 3.0%, 2.8%, and 5.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.
Trulicity: Hypersensitivity
Systemic hypersensitivity adverse reactions, sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling), occurred in 0.5% of adult patients on TRULICITY in clinical studies.
Trulicity: Injection site reactions
In the placebo-controlled studies in adults, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of TRULICITY-treated patients and in 0.0% of placebo-treated patients.
Trulicity: Injection site reactions in pediatric patients
In pediatric patients, the incidence of injection site reactions was 3.9% (2 patients) in the TRULICITY 0.75 mg group, 3.8% (2 patients) in the TRULICITY 1.5 mg group, and 2.0% (1 patient) in the placebo group.
Trulicity: PR interval prolongation and first-degree AV block
A mean increase from baseline in PR interval of 2-3 milliseconds was observed in TRULICITY-treated adult patients in contrast to a mean decrease of 0.9 milliseconds in placebo-treated patients. The adverse reaction of first-degree AV block occurred more frequently in patients treated with TRULICITY than placebo (0.9%, 1.7% and 2.3% for placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively).
Trulicity: Acute pancreatitis
An analysis of adjudicated events revealed 5 cases of confirmed pancreatitis in patients exposed to TRULICITY (1.4 cases per 1,000 patient years) versus 1 case in non-incretin comparators (0.88 cases per 1,000 patient years).
Trulicity: Amylase and lipase increase
Adult patients exposed to TRULICITY had mean increases from baseline in lipase and/or pancreatic amylase of 14% to 20%, while placebo-treated patients had mean increases of up to 3%.
Trulicity: Hair loss (alopecia), postmarketing
Skin and Subcutaneous Tissue: alopecia
Trulicity: Dysgeusia and dysesthesia, postmarketing
Neurologic: dysgeusia, dysesthesia
Warnings on the Trulicity label
Risk of Thyroid C-cell Tumors
Dulaglutide caused thyroid C-cell tumors in rats, and it is not known whether Trulicity causes them in people.
In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure [see Nonclinical Toxicology (13.1)]. Glucagon-like peptide-1 (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures.
Acute Pancreatitis
Inflammation of the pancreas, including fatal cases, has been observed, and Trulicity should be stopped if pancreatitis is suspected.
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including TRULICITY [see Adverse Reactions (6)].
Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
Using Trulicity together with insulin or a sulfonylurea may raise the risk of low blood sugar, including severe low blood sugar.
Patients receiving TRULICITY in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions (6.1) and Drug Interactions (7)].
Hypersensitivity Reactions
Serious allergic reactions such as anaphylaxis and angioedema have been reported, and Trulicity should be stopped if one occurs.
There have been postmarketing reports of serious hypersensitivity reactions including anaphylactic reactions and angioedema in patients treated with TRULICITY [see Adverse Reactions (6.2)]. If a hypersensitivity reaction occurs, discontinue TRULICITY; treat promptly per standard of care, and monitor until signs and symptoms resolve.
Acute Kidney Injury Due to Volume Depletion
Dehydration from nausea, vomiting or diarrhea has led to acute kidney injury in some patients.
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, including TRULICITY [see Adverse Reactions (6.2)]. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6.1)].
Severe Gastrointestinal Adverse Reactions
Trulicity can cause stomach and bowel side effects that are sometimes severe, and it is not recommended for people with severe gastroparesis.
Use of TRULICITY has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (6)]. In the pool of placebo-controlled trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving TRULICITY (0.75 mg 2.2%, 1.5 mg 4.3%) than placebo (1.4%).
Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy
Diabetic retinopathy complications were reported in a cardiovascular outcomes trial, so patients with a history of retinopathy should be monitored.
In a cardiovascular outcomes trial with a median follow up of 5.4 years involving patients with type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors, diabetic retinopathy complications occurred in patients treated with TRULICITY 1.5 mg (1.9%) and placebo (1.5%).
Acute Gallbladder Disease
Gallbladder problems such as gallstones and gallbladder inflammation have been reported with GLP-1 medicines.
Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing.
Pulmonary Aspiration During General Anesthesia or Deep Sedation
Because Trulicity slows stomach emptying, there have been rare reports with GLP-1 medicines of stomach contents entering the lungs during anesthesia or deep sedation.
TRULICITY delays gastric emptying [see Clinical Pharmacology (12.2)]. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.
If a side effect has you worried, tell your prescriber about signs of low blood sugar, above all if you also take insulin or a sulfonylurea, and about nausea, vomiting or diarrhea that leaves you dehydrated. Severe abdominal pain also needs a call. Signs of a serious allergic reaction need urgent medical care. Dose changes are for your prescriber to decide.
Trulicity (dulaglutide) is a type 2 diabetes medicine, and its label reports side effects in two sets of trials. The first is a pool of placebo-controlled trials in which 1,670 adults were exposed to 0.75 mg or 1.5 mg for a mean of 23.8 weeks. A placebo group gets an inactive treatment instead of the medicine. The second is a single trial of 1842 adults that compared 1.5 mg, 3 mg and 4.5 mg through 36 weeks, without a placebo group.
What are the most common side effects of Trulicity?
From the placebo-controlled pool, for 0.75 mg and 1.5 mg, then placebo:
- Nausea: 12.4% and 21.1%, with 5.3% on placebo.
- Diarrhea: 8.9% and 12.6%, with 6.7% on placebo.
- Vomiting: 6.0% and 12.7%, with 2.3% on placebo.
- Abdominal pain: 6.5% and 9.4%, with 4.9% on placebo.
- Decreased appetite: 4.9% and 8.6%, with 1.6% on placebo.
- Dyspepsia (indigestion): 4.1% and 5.8%, with 2.3% on placebo.
- Fatigue: 4.2% and 5.6%, with 2.6% on placebo.
Injection site reactions, such as rash and redness, were reported by 0.5% of Trulicity patients in the placebo-controlled studies.
Are side effects worse at 3 mg and 4.5 mg?
A little, according to the trial that added the higher doses to metformin. Through 36 weeks:
- Nausea: 13.4% on 1.5 mg, 15.6% on 3 mg and 16.4% on 4.5 mg.
- Diarrhea: 7.0%, 11.4% and 10.7%.
- Vomiting: 5.6%, 8.3% and 9.3%.
The two sets of trials differ in design and length, so don’t read their figures as one series.
How common are stomach side effects on Trulicity?
Counted together, gastrointestinal (stomach and bowel) reactions were reported by 32% of patients on 0.75 mg and 41% on 1.5 mg, against 21% on placebo. Severe ones were reported by 2.2% and 4.3%, against 1.4% on placebo. The label says Trulicity is not recommended in patients with severe gastroparesis (a stomach that empties very slowly).
Does Trulicity cause low blood sugar?
That depends on what you take it with, and the label breaks it out trial by trial. Added to metformin, glucose below 54 mg/dL was recorded in 0.3% of patients on 0.75 mg and 0.7% on 1.5 mg, and in no placebo patient. Combined with insulin glargine, the figure was 14.7% on 1.5 mg and 9.3% on placebo.
The highest rates came with a sulfonylurea, a type of diabetes pill (20% on 0.75 mg and 21% on 1.5 mg in a 78-week trial), and with mealtime insulin (77% and 69% in a 52-week trial). The label warns that insulin or a sulfonylurea may increase the risk, including severe hypoglycemia (low blood sugar). Adjusting those medicines is your prescriber’s decision.
What is the boxed warning, and what are the serious side effects?
Trulicity carries a boxed warning for thyroid C-cell tumors. A boxed warning is the strongest kind the FDA requires, set apart in a box on the label. Dulaglutide increases the incidence of these tumors in male and female rats after lifetime exposure, and the label says it’s unknown whether Trulicity causes them, “including medullary thyroid carcinoma (MTC), in humans.” Trulicity is contraindicated, meaning it must not be used, in patients with a personal or family history of MTC or with MEN 2 (Multiple Endocrine Neoplasia syndrome type 2).
The other warnings, with the label’s figures:
- Acute pancreatitis (inflammation of the pancreas): 5 confirmed cases in patients exposed to Trulicity, and 1 in comparator patients.
- Serious allergic reactions, including anaphylactic reactions (sudden and severe whole-body reactions) and angioedema, swelling under the skin. Systemic hypersensitivity (whole-body allergic) reactions occurred in 0.5% of adult patients in clinical studies.
- Acute kidney injury, mostly in patients dehydrated by nausea, vomiting or diarrhea.
- Diabetic retinopathy (eye damage from diabetes): in a cardiovascular outcomes trial with a median follow up of 5.4 years, complications occurred in 1.9% on Trulicity 1.5 mg and 1.5% on placebo.
- Gallbladder disease: in the same trial, serious events of acute gallbladder inflammation were reported in 0.5% on Trulicity and 0.3% on placebo.
- Pulmonary aspiration (stomach contents entering the lungs) during general anesthesia or deep sedation.
Heart rhythm. The label records a mean heart rate increase of 2 to 4 beats per minute. Sinus tachycardia, a fast but regular heart rhythm, was reported in 2.8% of patients on 0.75 mg and 5.6% on 1.5 mg, against 3.0% on placebo. First-degree AV block, a delay in the heart’s electrical signal, was reported in 1.7% and 2.3%, against 0.9%.
The label lists alopecia (hair loss) among reactions reported after approval. The safety guide sets these warnings out for all the medicines.
How many people stop Trulicity because of side effects?
The label gives the figure for stomach and bowel reactions: 1.3% of patients on 0.75 mg and 3.5% on 1.5 mg stopped treatment because of them, against 0.2% on placebo.
When to call your prescriber
The warnings show what a prescriber needs to hear about:
- Signs of low blood sugar, above all if you also take insulin or a sulfonylurea.
- Nausea, vomiting or diarrhea that leaves you dehydrated.
- Severe abdominal pain. The label says Trulicity should be stopped if pancreatitis is suspected.
- Signs of a serious allergic reaction, which needs urgent medical care.
- A history of diabetic retinopathy, or a planned procedure with anesthesia or deep sedation.
Dose changes are for your prescriber to decide. The Trulicity guide covers the rest of the label, and the side effects guide compares each reaction across medicines.
Frequently asked questions
What are the most common side effects of Trulicity?
Nausea, diarrhea, vomiting, abdominal pain, decreased appetite, dyspepsia (indigestion) and fatigue. In the label's pool of placebo-controlled trials in adults with type 2 diabetes, 12.4% of patients on 0.75 mg and 21.1% on 1.5 mg reported nausea, against 5.3% on placebo. Diarrhea was reported by 8.9% and 12.6%, against 6.7%.
Are side effects worse on Trulicity 3 mg or 4.5 mg?
Slightly, in the label's trial of the higher doses. Through 36 weeks, nausea was reported by 13.4% of patients on 1.5 mg, 15.6% on 3 mg and 16.4% on 4.5 mg. Vomiting was reported by 5.6%, 8.3% and 9.3%, and diarrhea by 7.0%, 11.4% and 10.7%. That trial had no placebo group.
Does Trulicity cause hair loss?
Hair loss isn't in the Trulicity trial tables. The label lists alopecia (hair loss) among the reactions reported after approval, under skin and subcutaneous tissue, and gives no rate for it. Reports of that kind are voluntary, so they show that hair loss has been reported with Trulicity, not how often it happens.
Is Trulicity safe?
The label doesn't answer with a yes or a no. It carries a boxed warning, the strongest kind the FDA requires: dulaglutide causes thyroid C-cell tumors in rats, and it's unknown whether Trulicity causes them in humans. Trulicity must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Whether it suits you is a decision for your prescriber.
What are the serious side effects of Trulicity?
The label's warnings cover acute pancreatitis, low blood sugar with insulin or a sulfonylurea, serious allergic reactions, acute kidney injury after dehydration, severe stomach and bowel reactions, diabetic retinopathy complications (eye damage from diabetes), acute gallbladder disease and pulmonary aspiration during anesthesia. Severe stomach and bowel reactions were reported by 2.2% of patients on 0.75 mg and 4.3% on 1.5 mg, against 1.4% on placebo.
Sources (3)
- 1.FDA label (DailyMed): Trulicity prescribing information, section 4
“TRULICITY is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
- 2.FDA label (DailyMed): Trulicity prescribing information, section 5.6
“TRULICITY is not recommended in patients with severe gastroparesis.”
- 3.
